Skip to main content
Erschienen in: Tumor Biology 2/2014

01.02.2014 | Research Article

Functional MUC4 suppress epithelial–mesenchymal transition in lung adenocarcinoma metastasis

verfasst von: Liuwei Gao, Jun Liu, Bin Zhang, Hua Zhang, Daowei Wang, Tiemei Zhang, Yang Liu, Changli Wang

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

The mucin MUC4 is a high molecular weight membrane-bound transmembrane glycoprotein that is frequently detected in invasive and metastatic cancer. The overexpression of MUC4 is associated with increased risks for several types of cancer. However, the functional role of MUC4 is poorly understood in lung adenocarcinoma. Using antisense-MUC4-RNA transfected adenocarcinoma cells, we discovered that the loss of MUC4 expression results in epithelial–mesenchymal transition (EMT). We found morphological alterations and the repression of the epithelial marker E-cadherin in transfected cells. Additionally, the loss of MUC4 caused the upregulation of the mesenchymal marker vimentin compared to control cells. Using a MUC4-knockdown versus control LTEP xenograft mice model (129/sv mice), we also found that EMT happened in lung tissues of MUC4-knockdown-LTEP xenograft mice. Moreover, antisense-MUC4-RNA transfected cells had a significantly increased cellular migration ability in vitro. The loss of MUC4 also occurred in lung adenocarcinoma patients with lymph node metastases. We further investigated MUC4 and found that it plays a critical role in regulating EMT by modulating β-catenin. Taken together, our study reveals a novel role for MUC4 in suppressing EMT and suggests that the assessment of MUC4 may function as a prognostic biomarker and could be a potential therapeutic target for lung adenocarcinoma metastasis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Nakamura N et al. Identification of tumour markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 2006;25(30):4245–55.PubMedCrossRef Nakamura N et al. Identification of tumour markers and differentiation markers for molecular diagnosis of lung adenocarcinoma. Oncogene. 2006;25(30):4245–55.PubMedCrossRef
3.
Zurück zum Zitat Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 2007;185(1–3):7–19.PubMedCrossRef Chaffer CL, Thompson EW, Williams ED. Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs. 2007;185(1–3):7–19.PubMedCrossRef
5.
Zurück zum Zitat Shintani Y et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1794–804. discussion 1804.PubMedCrossRef Shintani Y et al. Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. Ann Thorac Surg. 2011;92(5):1794–804. discussion 1804.PubMedCrossRef
6.
Zurück zum Zitat Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 2012;17(7):1048–59.PubMedCrossRef Sato M, Shames DS, Hasegawa Y. Emerging evidence of epithelial-to-mesenchymal transition in lung carcinogenesis. Respirology. 2012;17(7):1048–59.PubMedCrossRef
7.
Zurück zum Zitat Kim AN et al. Fyn mediates transforming growth factor-beta1-induced downregulation of E-cadherin in human A549 lung cancer cells. Biochem Biophys Res Commun. 2011;407(1):181–4.PubMedCrossRef Kim AN et al. Fyn mediates transforming growth factor-beta1-induced downregulation of E-cadherin in human A549 lung cancer cells. Biochem Biophys Res Commun. 2011;407(1):181–4.PubMedCrossRef
8.
Zurück zum Zitat Puisieux A. Role of epithelial-mesenchymal transition in tumour progression. Bull Acad Natl Med. 2009;193(9):2017–32. discussion 2032–4.PubMed Puisieux A. Role of epithelial-mesenchymal transition in tumour progression. Bull Acad Natl Med. 2009;193(9):2017–32. discussion 2032–4.PubMed
9.
Zurück zum Zitat Lee JM et al. The epithelial–mesenchymal transition: new insights in signalling, development, and disease. J Cell Biol. 2006;172(7):973–81.PubMedCrossRef Lee JM et al. The epithelial–mesenchymal transition: new insights in signalling, development, and disease. J Cell Biol. 2006;172(7):973–81.PubMedCrossRef
11.
Zurück zum Zitat Nozawa N et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract. 2006;202(9):639–50.PubMedCrossRef Nozawa N et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract. 2006;202(9):639–50.PubMedCrossRef
12.
Zurück zum Zitat Kwon KY et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumour histology and patient survival. Arch Pathol Lab Med. 2007;131(4):593–8.PubMed Kwon KY et al. MUC4 expression in non-small cell lung carcinomas: relationship to tumour histology and patient survival. Arch Pathol Lab Med. 2007;131(4):593–8.PubMed
13.
Zurück zum Zitat Carraway KL et al. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2001;6(3):323–37.PubMedCrossRef Carraway KL et al. Muc4/sialomucin complex in the mammary gland and breast cancer. J Mammary Gland Biol Neoplasia. 2001;6(3):323–37.PubMedCrossRef
14.
Zurück zum Zitat Singh AP et al. Inhibition of MUC4 expression suppresses pancreatic tumour cell growth and metastasis. Cancer Res. 2004;64(2):622–30.PubMedCrossRef Singh AP et al. Inhibition of MUC4 expression suppresses pancreatic tumour cell growth and metastasis. Cancer Res. 2004;64(2):622–30.PubMedCrossRef
15.
Zurück zum Zitat Ogata S et al. Mucin gene expression in colonic tissues and cell lines. Cancer Res. 1992;52(21):5971–8.PubMed Ogata S et al. Mucin gene expression in colonic tissues and cell lines. Cancer Res. 1992;52(21):5971–8.PubMed
16.
Zurück zum Zitat Lopez-Ferrer A et al. MUC4 expression is increased in dysplastic cervical disorders. Hum Pathol. 2001;32(11):1197–202.PubMedCrossRef Lopez-Ferrer A et al. MUC4 expression is increased in dysplastic cervical disorders. Hum Pathol. 2001;32(11):1197–202.PubMedCrossRef
17.
Zurück zum Zitat Shibahara H et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004;39(1):220–9.PubMedCrossRef Shibahara H et al. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type. Hepatology. 2004;39(1):220–9.PubMedCrossRef
18.
Zurück zum Zitat Majhi PD et al. Pathobiological implications of MUC4 in non-small-cell lung cancer. J Thorac Oncol. 2013;8(4):398–407.PubMedCrossRef Majhi PD et al. Pathobiological implications of MUC4 in non-small-cell lung cancer. J Thorac Oncol. 2013;8(4):398–407.PubMedCrossRef
19.
Zurück zum Zitat Giuntoli RN et al. Mucin gene expression in ovarian cancers. Cancer Res. 1998;58(23):5546–50.PubMed Giuntoli RN et al. Mucin gene expression in ovarian cancers. Cancer Res. 1998;58(23):5546–50.PubMed
20.
Zurück zum Zitat Weed DT et al. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes. Laryngoscope. 2004;114(8 Pt 2 Suppl 101):1–32.PubMedCrossRef Weed DT et al. MUC4 and ErbB2 expression in squamous cell carcinoma of the upper aerodigestive tract: correlation with clinical outcomes. Laryngoscope. 2004;114(8 Pt 2 Suppl 101):1–32.PubMedCrossRef
21.
Zurück zum Zitat Weed DT et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck. 2004;26(4):353–64.PubMedCrossRef Weed DT et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck. 2004;26(4):353–64.PubMedCrossRef
22.
Zurück zum Zitat Braun J et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29(29):4237–44.PubMedCrossRef Braun J et al. Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas. Oncogene. 2010;29(29):4237–44.PubMedCrossRef
23.
Zurück zum Zitat Vuoriluoto K et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436–48.PubMedCrossRef Vuoriluoto K et al. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011;30(12):1436–48.PubMedCrossRef
24.
25.
Zurück zum Zitat Hiscox S et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118(2):290–301.PubMedCrossRef Hiscox S et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. Int J Cancer. 2006;118(2):290–301.PubMedCrossRef
26.
Zurück zum Zitat Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49.PubMedCentralPubMedCrossRef Li J, Zhou BP. Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.PubMedCrossRef Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.PubMedCrossRef
28.
Zurück zum Zitat Wang C et al. The function of SARI in modulating epithelial–mesenchymal transition and lung adenocarcinoma metastasis. PLoS One. 2012;7(9):e38046.PubMedCentralPubMedCrossRef Wang C et al. The function of SARI in modulating epithelial–mesenchymal transition and lung adenocarcinoma metastasis. PLoS One. 2012;7(9):e38046.PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Horn G et al. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumour cells induced by truncated MUC1. Exp Cell Res. 2009;315(8):1490–504.PubMedCrossRef Horn G et al. ERK and PI3K regulate different aspects of the epithelial to mesenchymal transition of mammary tumour cells induced by truncated MUC1. Exp Cell Res. 2009;315(8):1490–504.PubMedCrossRef
30.
Zurück zum Zitat Ponnusamy MP et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010;29(42):5741–54.PubMedCentralPubMedCrossRef Ponnusamy MP et al. MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010;29(42):5741–54.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Conacci-Sorrell M et al. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signalling, Slug, and MAPK. J Cell Biol. 2003;163(4):847–57.PubMedCrossRef Conacci-Sorrell M et al. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of beta-catenin signalling, Slug, and MAPK. J Cell Biol. 2003;163(4):847–57.PubMedCrossRef
32.
Zurück zum Zitat Asnaghi L et al. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene. 2010;29(19):2760–71.PubMedCentralPubMedCrossRef Asnaghi L et al. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene. 2010;29(19):2760–71.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Lee W et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010;465(7297):473–7.PubMedCrossRef Lee W et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010;465(7297):473–7.PubMedCrossRef
34.
Zurück zum Zitat Hata A et al. Erlotinib after Gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011;74(2):268–73.PubMedCrossRef Hata A et al. Erlotinib after Gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011;74(2):268–73.PubMedCrossRef
35.
Zurück zum Zitat Longo F et al. Long-term survival in a smoking Caucasian male patient treated with Gefitinib for spinal cord compression secondary to lung cancer. Onkologie. 2011;34(6):326–8.PubMedCrossRef Longo F et al. Long-term survival in a smoking Caucasian male patient treated with Gefitinib for spinal cord compression secondary to lung cancer. Onkologie. 2011;34(6):326–8.PubMedCrossRef
36.
37.
Zurück zum Zitat Weng JH et al. Pituitary FDG uptake in a patient of lung cancer with bilateral adrenal metastases causing adrenal cortical insufficiency. Clin Nucl Med. 2011;36(8):731–2.PubMedCrossRef Weng JH et al. Pituitary FDG uptake in a patient of lung cancer with bilateral adrenal metastases causing adrenal cortical insufficiency. Clin Nucl Med. 2011;36(8):731–2.PubMedCrossRef
38.
Zurück zum Zitat Tsutsumida H et al. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55(2):195–203.PubMedCrossRef Tsutsumida H et al. MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer. 2007;55(2):195–203.PubMedCrossRef
Metadaten
Titel
Functional MUC4 suppress epithelial–mesenchymal transition in lung adenocarcinoma metastasis
verfasst von
Liuwei Gao
Jun Liu
Bin Zhang
Hua Zhang
Daowei Wang
Tiemei Zhang
Yang Liu
Changli Wang
Publikationsdatum
01.02.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1178-0

Weitere Artikel der Ausgabe 2/2014

Tumor Biology 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.